Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye diseases
Biotech
4DMT restructures pipeline, extending cash runway through 2028
4DMT is axing two clinical programs and shutting off funds for three other assets, with resources to be pivoted toward gene therapy 4D-150.
Gabrielle Masson
Jan 10, 2025 2:00pm
Oculis peptidomimetic helps protect eyes from nerve inflammation
Jan 6, 2025 5:27am
Aurion's regenerative med improves vision in phase 1/2 trial
Dec 18, 2024 7:00am
2 eye disease biotechs merge, set sights on FDA approval
Dec 12, 2024 11:05am
GenSight enters final weeks of cash runway
Oct 25, 2024 3:19am
Despite ph. 3 miss, Alkeus sees path forward for eye disease med
Sep 17, 2024 10:58am
